X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy’s: Benefiting from an R & D led re–rating - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 11, 2000

    Dr. Reddy’s: Benefiting from an R & D led re–rating

    Dr. Reddy’s Laboratories (DRL) has shot up almost 24% in the last one month. The company has been one of the pro–active companies among Indian pharmaceutical companies in preparing for the product patent regime.

    As per the C–Marc Prescription Audit Data, the company is among the top 5 domestic formulation companies with a 1.9% share of all drugs prescribed by doctors.

    The company’s product profile is focused on anti–ulcer, anti–pain and anti–infectives segment. For its R & D efforts it has focused on the anti–diabetes segment so far (more on that later). It is this focus on its core competence that has enabled DRL to report a 34% growth in finished dosages in FY2000 when the overall formulation market grew by 9.2%. These were led by a 25% growth in Omez (the company's anti–ulcer drug), a 28% growth in Nise (anti–pain) and a 49% growth in Ciprolet (anti–infectives). The company’s top six brands Omez, Nise, Ciprolet, Stamlo, Enam and Stamlo Beta contributed 57% to the total turnover of the company. Ciprolet's success is particularly noteworthy since the anti–infectives market has grown by hardly 4%.

    Also, the Russian problem has become less relevant with Russia’s diminishing importance due to the company’s aggressive expansion in markets such as China and Brazil. Infact the company’s exports grew by 39% to non–Russian markets (albeit over a smaller base of Rs 180 m).

    Dr. Reddy's pipeline
    Molecule Therapeutic area Current Status
    DRF 2725 Anti–diabetes Licensed to Novo Nordisk in June 1998;
    Entered phase II of clinical trials in Aug 2000
    DRF 2593 Anti–diabetes Licensed to Novo Nordisk in March 1997;
    Entered phase II of clinical trials in Mar 2000
    DRF 1644 Anti–cancer Contrated to NDDO, a clinical research organisation;
    late pre–clinical studies
    DRF MDX8 Metabolic disorder drug Completed pre–clinical;
    under licensing negotaitions
    DRF NPCC Anti–diabetes Pre–clinical complete;
    Initiating licensing negotiations
    DRF 4367 Cox–2 inhibitor Pre–clinical complete;
    IND application in the USA proposed
    DRF ACXX Anti–cancer compound late pre–clinical development

    As far as R & D is concerned in a sense, it was DRL, which pioneered pharmaceutical Research & Development among Indian pharmaceutical companies when it licensed its anti–diabetes insulin sensitiser DRF 2593 to a Danish company Novo Nordisk. The company arguably has the best R & D pipeline in the country with almost five molecules in pre–clinical trials.

    What seems to be driving the stock however, is the consolidation of group interests. The acquisition of American Remedies and the amalgamation with Cheminor Drugs would catapult DRL to being the third largest pharmaceutical player in India. We expect the company to report a net profit in the range of Rs 1100 m in the current year. This implies an EPS of over Rs 34 on the consolidated equity and an earning multiple of over 40 times FY2001 earnings.

    While there seems to be no dramatic undervaluation at current levels, the company has definitely benefited from an R & D led re–rating.

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy’s: Benefiting from an R & D led re–rating". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 24, 2017 12:47 PM

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS